Fremanezumab: Cost-Effective Relief for Chronic Migraine

By Thanusha Pillay

July 3, 2024


Migraine is a complex neurological condition marked by moderate to severe headaches that can last for hours to days, with lingering symptoms and extreme tiredness post-attack. The International Headache Society defines chronic migraine, the most severe form, as having headaches on 15 or more days per month for over three months, with migraine characteristics on at least 8 days per month. Chronic migraine affects 10-20% of migraine sufferers and significantly impacts health-related quality of life of the patient and their families.

Migraine is highly prevalent, with over 200 000 patients in the Netherlands. It is more common in women, particularly during their childbearing and working years. Globally, migraines contribute significantly to disability, being the 14th leading cause of disability-adjusted life-years in 2019 and the top cause of years lived with disability for those aged 15-49. This results in a substantial economic burden, with costs in the Netherlands estimated between €2.3–4.2 billion annually, potentially reaching up to €5 billion.

There are preventative treatments for migraine, one of the newest drugs being fremanezumab, a monoclonal antibody designed to prevent migraines. It works by targeting and inhibiting the calcitonin gene-related peptide (CGRP), a molecule involved in migraine attacks. Clinical trials have shown that fremanezumab significantly reduces the frequency of monthly migraine days (MMD), improving patients’ quality of life.

Fremanezumab vs. Supportive Care

This Dutch study published in BMC Neurology explores the cost-effectiveness of fremanezumab, comparing it with best supportive care (BSC) and examining its long-term benefits. The primary patient population included those with chronic migraine who did not respond to topiramate, valproate, or onabotulinumtoxinA. In the Netherlands, healthcare providers consider fremanezumab a last-line treatment for these patients. The model began with a decision tree to evaluate treatment response after 12 weeks. Responders continued treatment, while non-responders discontinued. Patients then entered a semi-Markov model with two health states (on treatment; off treatment) and an absorbing state of death (natural causes). Within the main health states, patients were distributed across 29 monthly migraine days. The model structure is illustrated in Figure 1 below.

Fig. 1

Figure 1. Model structure. A responder was a patient with a ≥ 30% reduction in MMD from baseline during the 12 weeks after therapy initiation. MMD, monthly migraine days.

Economic Evaluation

The researchers performed the study from a societal perspective and included an economic evaluation of fremanezumab involving direct and indirect costs. Direct costs include medical expenses such as hospitalisation, emergency department visits, and medication. Indirect costs encompass productivity losses due to missed workdays and the need for informal care.

Cost-Effectiveness Analysis

A cost-effectiveness analysis compares the costs and health outcomes of fremanezumab with BSC. The primary measure used is the incremental cost-effectiveness ratio (ICER), which represents the cost per quality-adjusted life year (QALY) gained. An ICER below the willingness-to-pay (WTP) threshold indicates that the treatment is cost-effective.

Key Findings

  1. Costs Compared to Supportive Care: In the primary study population, fremanezumab is cost-saving compared with supportive care, saving €2 514.

  2. Long-Term Benefits: Over a 10-year time horizon, fremanezumab remained cost-effective, with an ICER of €4 620 per QALY. This is well below the WTP threshold of €50 000, demonstrating its sustained economic value over time.

  3. Indirect Costs: Including indirect costs generally made fremanezumab dominant, meaning it was both more effective and less costly than BSC. When productivity losses are excluded, the ICER for fremanezumab increases significantly to €17 498 per QALY. Despite this increase, the ICER remains within the range considered cost-effective. Moreover, including informal care costs also results in substantial cost savings.

  4. Most Impactful Variables: Monthly migraine days, starting age of treatment, fremanezumab cost, and response rate were the most impactful variables on the model outcomes. Fremanezumab consistently proved its high cost-effectiveness compared to supportive care.

Fig. 2
Figure 2. A) Tornado plot of sensitivity analysis results. B and C, respectively)  scatter plot of and WTP curve for PSA results. ICER, incremental cost-effectiveness ratio; MMD, monthly migraine days; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life-year; WTP, willingness-to-pay.


This paper presents the first published cost-effectiveness study for fremanezumab, demonstrating its substantial economic impact in migraine management. It offers a cost-effective solution for reducing the burden of migraines, improving patient outcomes, and lowering overall healthcare costs. As healthcare systems continue to seek value-based treatments, fremanezumab stands out as a promising option.

Reference url

Recent Posts

Cutaneous Malignant Melanoma Treatment

Forecasting Innovations in Cutaneous Malignant Melanoma Treatment in Sweden

“Shaping Melanoma Care: Insights for UV Safety Month”

🌟 Exciting Insights! Learn how system dynamics modelling shapes the future of cutaneous malignant melanoma care during UV Safety Month. Discover key strategies for better healthcare planning and patient outcomes. #SyenzaNews #UVSafetyMonth #HealthcarePlanning #MelanomaCare #PreventiveInterventions 🏥

skin cancer primary prevention

Enhancing Skin Cancer Prevention in a Primary Care Setting

🌞 Discover the latest strategies in skin cancer primary prevention! From innovative risk assessment tools to new technologies, learn how primary care can play a pivotal role in reducing skin cancer rates.
🩺👩‍⚕️👨‍⚕️ #SyenzaNews #Healthcare #SkinCancerPrevention #PrimaryCare #Innovation

Valvular heart disease in Saudi Arabia

Addressing Valvular Heart Disease in Saudi Arabia

#SyenzaNews 🚀 Valvular heart disease (VHD) is a growing concern in Saudi Arabia, especially among the ageing population.
Discover the current challenges and actionable recommendations to enhance VHD care.

Let’s work together to improve awareness, detection, and treatment! #Healthcare #Cardiology #SaudiArabia #HealthyAging 🌟

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.